Markers of tumor angiogenesis and proteolysis independently define high- and low-risk subsets of node-negative breast cancer patients

Journal of Clinical Oncology

Volumn 16, Issue 9, 1998, Pages 3129-3136

  Eppenberger, Urs ^a   Kueng, Willy ^a   Schlaeppi, Jean Marc ^a   Roesel, Johannes L ^a   Benz, Christopher ^a   Mueller, Heinz ^a   Matter, Alex ^a   Zuber, Markus ^a   Luescher, Klaus ^a   Litschgi, Mario ^a   Schmitt, Manfred ^a   Foekens, John A ^a   Eppenberger Castori, Serenella ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIN; BASIC FIBROBLAST GROWTH FACTOR; STEROID RECEPTOR; TUMOR MARKER; UROKINASE; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROVASCULATURE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN DEGRADATION; TUMOR BIOPSY; TUMOR VASCULARIZATION;

EID: 0344109584     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.9.3129     Document Type: Article

References (53)

1. Early Breast Cancer Trialists' Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, and immune therapy; 133 randomized trials involving 31.000 recurrences and 24.000 death among 75.000 women. Lancet 339:1-15, 71-85, 1992
2. Goldhirsch A, Wood WC, Senn HJ, et al: Fifth International Conference on Adjuvant Therapy of Breast Cancer, St. Gallen March 1995. International Consensus Panel on the Treatment of Primary Breast Cancer. Eur J Cancer 31A:1754-1759, 1995
3. Hudis CA, Norton L: Adjuvant drug therapy for operable breast cancer. Semin Oncol 23:475-493, 1996
4. Bonadonna G, Valagussa P: Primary chemotherapy in operable breast cancer. Semin Oncol 23:464-474, 1996
5. Sledge GW Jr: Adjuvant therapy for early stage breast cancer. Semin Oncol 23:51-54, 1996 (suppl 2)
6. Pepper MS, Montesano R: Proteolytic balance and capillary morphogenesis. Cell Differ Dev 32: 319-331, 1990
7. Ellis LM, Fidler IJ: Angiogenesis and metastasis. Eur J Cancer 32A:2451-2460, 1996
8. Brünner N, Pyke C, Hansen CH, et al: Urokinase plasminogen activator (uPA) and its type 1 inhibitor (PAI-1): Regulators of proteolysis during cancer invasion and prognostic parameters in breast cancer. Breast Cancer Treat Res 71:399-309, 1994
9. Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: Update of the biological background and overview of the Vicenza studies. Eur J Cancer 32A:2485-2493, 1996
10. Pezzella F, Di Bacco A, Andreola S, et al: Angiogenesis in primary lung cancer and lung secondaries. Eur J Cancer 32A:2494-2500, 1996
11. Chung YS, Maeda K, Sowa M: Prognostic value of angiogenesis in gastro-intestinal tumours. Eur J Cancer 32A:2501-2505, 1996
12. Weidner N: Intratumoral vascularity as a prognostic factor in cancer of the urogenital tract. Eur J Cancer 32A:2506-2512, 1996
13. Dvorak HF, Brown LF, Detmar M, et al: Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am J Pathol 146:1029-1039, 1995
14. Toi M, Kazuo I, Suzuki H, et al: Tumor angiogenesis in breast cancer its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
15. Karaiossifidi H, Kouri E, Arvaniti H, et al: Tumor angiogenesis in node-negative breast cancer: Relationship with relapse free survival. Anticancer Res 16:4001-4002, 1996
16. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364, 1996
17. Folkman J, Shing Y: Angiogenesis. J Biol Chem 267:10931-10940, 1992
18. Weidner N: Tumor angiogenesis: Review of current applications in tumor prognostication. Semin Diagn Pathol 10:302-313, 1993
19. Houck KA, Ferrara N, Winer J, et al: The vascular endothelial growth factor family: identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol Endocrinol 5:1806-1814, 1991
20. Ferrara N, Davis-Smyth T: The biology of vascular endothelial growth factor. Endocrine Rev 18:4-25, 1997
21. Risau W: Mechanisms of angiogenesis. Nature 386:671-674, 1997
22. Toi M, Hoshina S, Takayanagi T, et al: Association of vascular endothelial growth factor expression with tumor angiogenesis and early relapse in primary breast cancer. Jpn J Cancer Res 85:1045-1049, 1994
23. Toi M, Kondo S, Suzuki H, et al: Quantitative analysis of vascular epithelial growth factor in primary breast cancer. Cancer 77:1101-1106, 1996
24. Toi M, Inada K, Suzuki H, et al: Tumor angiogenesis in breast cancer: Its importance as a prognostic indicator and the association with vascular endothelial growth factor expression. Breast Cancer Res Treat 36:193-204, 1995
25. Gasparini G, Toi M, Gion M, et al: Prognostic significance of vascular epithelial growth factor protein in nodal-negative breast carcinoma. J Natl Cancer Inst 89:139-147, 1997
26. McGuire WL, Tandon AK, Allred DC, et al: How to use prognostic factors in axillary node negative breast cancer patients. J Natl Cancer Inst 82:1006-1015, 1990
27. Dhingra K, Hortobagyi GN: Critical evaluation and prognostic factors. Semin Oncol 23:436-445, 1996
28. Clark GM: Do we really need prognostic factors for breast cancer? Breast Cancer Res Treat 30:117-126, 1994
29. Foekens JA, Schmitt M, van Putten WLJ, et al: Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res 52:6101-6105, 1992
30. Jänicke F, Schmitt M, Pache L, et al: Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat 24:195-208, 1993
31. Foekens JA, Schmitt M, van Putten W, et al: Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12:1648-1658, 1994
32. Foekens JA, Portengen H, van Putten WLJ, et al: Prognostic value of estrogen and progesterone receptors measured by enzyme immunoassays in human breast tumor cytosols. Cancer Res 49:5823-5828, 1989
33. Schlaeppi JM, Eppenberger U, Martiny-Baron G, et al: Chemiluminescence immunoassay for vascular endothelial growth factor in tumor-tissue homogenates. Clin Chem 42:1777-1784, 1996
34. Barlow RE, Bartholomew DJ, Bremmer JM, et al: Statistical Interference Under Order Restrictions. London, United Kingdom, Wiley, 1972
35. Breimann L, Friedman JH, Olsheu RA, et al: Classification and Regression Trees. Monterey, CA, Wadsworth and Brooks/Cole, 1984
36. Mantel N: Evaluation of survival data and the two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
37. Cox DR: Regression models and life-tables. J R Stat Soc (B) 34:187-220, 1972
38. Tibshirani R: A plain man's guide to the proportional hazards model. Clin Invest Med 5:63-68, 1982
39. Levine MN, Browman G, Gent M, et al: When is a prognostic factor useful?: A guide for the perplexed. J Clin Oncol 9:348-356, 1991
40. Toi M, Gion M, Biganzoli E, et al: Co-determination of the angiogenic factors thymidine phosphorylase and vascular endothelial growth factor in node-negative breast cancer: Prognostic implications. Angiogenesis 1:71-83, 1997
41. Bläser J, Thomssen C, Schmitt M, et al: Angiogenin is a valuable prognostic factor in nodal-negative breast cancer, in Schmitt M, Graeff H, Kindermann G (eds): Prospects in Diagnosis and Treatment of Breast Cancer. Amsterdam, the Netherlands, Elsevier Science, 1994, pp 223-227
42. Czubayko F, Liandet-Coopman ED, Aigner A, et al: A secreted FGF-binding protein can serve as the angiogenic switch in human cancer. Nature Med 3:1137-1140, 1997
43. Rak J, Kerbel RS: bFGF and tumor angiogenesis - Back in the limelight? Nat Med 3:1083-1084, 1997
44. Jänicke F, Pache L, Schmitt M, et al: Both the cytosols and detergent extracts of breast cancer tissue are suited to evaluate the prognostic impact of uPA and PAI-1. Cancer Res 54:1527-2530, 1994
45. Schmitt M, Thomssen C, Ulm K, et al: Time-varying prognostic impact of tumor biological factors urokinase (uPA), PAI-1, and steroid hormone receptor status in primary breast cancer. Br J Cancer 76:306-311, 1997
46. Pepper MS, Ferrara N, Orci L, et al: Vascular endothelial growth factor (VEGF) induces plasminogen activators and plasminogen activator inhibitor type 1 in microvascular endothelial cells. Biochem Biophys Res Commun 181:902-908, 1991
47. Mandriota S, Montesano R, Orci L, et al: Vascular endothelial growth factor increases urokinase receptor expression in vascular endothelial cells. J Biol Chem 270:9709-9716, 1995
48. Claffey KP, Brown LF, del Aguila LF, et al: Expression of vascular permeability factor/vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis and experimental metastasis. Cancer Res 56:172-181, 1996
49. Ferrara N: Vascular endothelial growth factor. Eur J Cancer 32A:2413-2422, 1996
50. Hillner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. N Engl J Med 324:160-168, 1991
51. Folkman J: Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 333:1757-1763, 1995
52. Bicknell R, Phil D, Harris, AL: Mechanisms and therapeutic implications of angiogenesis. Curr Opin Oncol 8:60-66, 1996
53. Skobe M, Rockwell P, Goldstein N, et al: Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222-1227, 1997